Selank benefits, as the research describes them, are anxiolytic: reduced anxiety symptoms in patients treated for anxiety disorders, supported by neurochemical work in rats. Not one of the studied benefits is a muscle benefit. That is not an omission waiting to be filled in, it is what the compound was developed for.
The vendor we point lifters to
Selank from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
The published certificate for lot 29-01260229 assays this vial at 12.29 mg against a 10 mg label, and reports no endotoxin or sterility testing. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 21, 2026.
Most articles on a body composition site would now start building a bridge. This one is not going to, because the bridge does not exist. No study in any species has measured lean mass, strength, power, body fat or muscle protein synthesis after administering this peptide, and no mechanism connecting it to those outcomes has been described in any organism.
What follows is the actual benefit list, the one honest indirect argument, and where that argument stops.
A peptide with a therapeutic history, not a performance one
The origin explains the shape of the evidence. Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring peptide fragment with immune signalling activity, and it was developed in Russia as a treatment for anxiety.
That is a pharmaceutical development path, not a sports one. The endpoints chosen, the populations recruited and the comparators used all belong to psychiatry. When people encounter the compound through a peptide vendor, they meet it in a catalogue beside growth hormone secretagogues and healing peptides, and the catalogue implies a shared purpose the research does not share.
Categories on a product page are a merchandising decision. They are not a mechanism, and they are the single most common source of confusion about this molecule.
Which Selank benefits have research behind them
Anxiety reduction is the central claim and the one with genuine clinical work behind it. Russian clinical research in patients with anxiety disorders has reported symptom improvement, including studies comparing it against benzodiazepine treatment. That literature is real and should not be waved away because it is unfamiliar.
An absence of sedation and of dependence is the second claim, and it is a characterisation drawn from that same clinical literature rather than an established fact in the Western record. It is worth reporting as what the Russian work describes, and worth flagging as something no FDA, EMA or MHRA review has examined.
Neurochemical effects are the mechanistic layer. Rat studies have reported changes in brain serotonin metabolism and in expression of brain derived neurotrophic factor. Work in human blood plasma has described slowed breakdown of endogenous enkephalins. These are laboratory findings that make an anxiolytic profile plausible, and they are not clinical outcomes.
Cognitive and attention effects appear in vendor copy and are the weakest link in the chain. Some Russian work has examined effects on cognitive measures alongside anxiety, and the results reported there are modest and specific rather than the general nootropic claim that circulates online.
The immune fragment it came from
Because the compound is derived from tuftsin, a naturally occurring peptide fragment with described immune signalling activity, vendors occasionally build a recovery or immune claim out of the lineage.
The lineage is real and the inference is not. A derivative is a distinct molecule, modified precisely because the parent fragment was unsuitable, and the research programme that followed measured anxiety outcomes rather than immune ones. Nothing published on this peptide reports an effect on recovery from training, on inflammation after exercise, or on any immune outcome in a trained person, in any species.
Ancestry explains where a molecule came from. It is not evidence about what it does.
Five questions, answered without hedging
Does Selank build muscle?
No study in any organism has measured muscle mass after administering it. There is no evidence of an anabolic effect, and no mechanism connecting the compound to muscle has been described.
Does it affect myostatin?
Nothing in the literature describes any action on that pathway, in rats, in cells or in humans.
Is it a legitimate medicine?
In Russia, yes. It is a registered medicine there, prescribed and supported by clinical research. Elsewhere it holds no authorisation and is sold as a research chemical.
Are there Western trials of it?
No genuine ones. Trial registry searches return records that mention the term while studying something else entirely, including epilepsy drugs, transcranial stimulation for dyslexia, telephone psychotherapy and neurofeedback. Reading the records leaves no Selank trial.
Would it improve my training?
Not established. No study in any species has measured training output, adherence, recovery or performance after administration, so the question has never been examined.
The ageing muscle question this site has to answer
If the benefits are anxiolytic, why does the compound appear in lifting conversations at all? There is a real answer, and it needs stating carefully because it is easy to inflate.
Lean mass after forty is protected mainly by continuity. Training results accumulate across years, and what interrupts them is often not an injury. It is a stretch of poor sleep, a stressful quarter at work, a period of anxiety that makes hard sessions feel impossible and makes food intake erratic. Those states degrade adherence and recovery in humans generally, and interrupted training is one of the main routes by which a body over forty quietly loses ground.
So the argument goes: a treatment that reduced anxiety could protect the consistency that protects muscle. As a chain of reasoning it is coherent.
Now the honest limits. Every link past the first is untested for this compound. No study has followed people using Selank and measured training adherence, session quality, sleep architecture, recovery or body composition, in any population. The clinical research concerns patients with diagnosed anxiety disorders, which is a different group from a stressed lifter, and improvements measured in a clinical population routinely fail to appear in people without the diagnosis.
A further complication is specific to this audience. Stress and anxiety affect training through several routes at once in humans: sleep, appetite, motivation, and the willingness to do hard sessions on the days they are least appealing. An intervention improving one of those routes would not necessarily improve the outcome, because which route dominates for a given person is unknown and unmeasured. Trials in anxiety disorders measure none of them.
There is also the obvious point that if anxiety is genuinely affecting your training and your life, the interventions with substantial human evidence behind them are clinical ones available from a doctor, not an unregulated vial ordered online.
The population gap that decides whether any of this applies
Clinical research recruits people with a diagnosis, and that choice shapes what the results can mean for anyone else.
The studies behind this compound's use in Russia enrolled patients with anxiety disorders. In that group, symptom scores start high, which leaves room to improve and makes an effect easier to detect. Someone without the diagnosis, stressed by work and training but functioning, starts much closer to the floor of the same scale.
This is a general pattern in medicine rather than a criticism of the research. Treatments producing clear benefit in a clinical population frequently produce little or nothing in people who do not have the condition, because the deficit being corrected is smaller or absent.
So the honest translation for a reader here is narrow. Real clinical work exists, in patients, for a condition, inside one regulatory system. Whether any of it applies to a healthy lifter chasing a marginal gain has not been tested in any study, and assuming it does is the largest unspoken leap in the whole topic.
Claimed benefit against support
| Claimed benefit | What supports it | Organism |
|---|---|---|
| Reduces anxiety symptoms | Clinical research within the Russian system | Human |
| Works without sedation or dependence | Characterisation from that same literature, not independently reviewed | Human |
| Alters serotonin metabolism | Neurochemical studies | Rat |
| Increases BDNF expression | Brain tissue studies | Rat |
| Slows enkephalin breakdown | Laboratory work in plasma | Human, in vitro |
| Improves cognition broadly | Overstated relative to the source work | Human, limited |
| Increases lean mass | Nothing published | None |
| Improves strength or performance | Nothing published | None |
| Improves recovery from training | Nothing published | None |
| Protects training consistency | A hypothesis, never tested | None |
The bottom four rows are the ones this audience came for, and all four are empty.
Two regulatory facts that both matter
Selank is approved and used as a medicine in Russia, with real clinical literature behind it. It has no marketing authorisation from the FDA, the EMA or the MHRA, and no genuine Western trial has ever been registered.
Neither fact cancels the other, and both get misused. Presenting Russian registration as equivalent to a Western approval overstates the evidence a reader can access and check. Dismissing that clinical work as nonexistent understates it. What a buyer outside Russia actually receives, meanwhile, is neither the registered medicine nor a trial supply. It is a research chemical whose identity, purity and quantity are attested by the seller and verified by nobody, which is a separate problem from what the molecule does.